☆ 4.7 Article

Original Research Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma

EUROPEAN JOURNAL OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley et al.

Summary: This study examined the efficacy of adding the immune checkpoint inhibitor pembrolizumab to the standard chemotherapy regimen for advanced biliary tract cancer. The results showed that the combination treatment significantly improved overall survival compared to chemotherapy alone.

LANCET (2023)

Add to Collection

Article Gastroenterology & Hepatology

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

Do-Youn Oh et al.

Summary: In patients with advanced biliary tract cancer, gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety, with an objective response rate of 66%. The most common adverse events were hematological, with no unexpected safety events observed.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma

Nai-Jung Chiang et al.

Summary: This study aimed to investigate the tumor immune microenvironment (TIME) in Epstein-Barr virus (EBV)-associated lymphoepithelioma-like cholangiocarcinoma (EBV-LELCC) and its correlation with clinical outcomes. The results showed that increased immune cell infiltration and changes in immune cell types in TIME were associated with better survival. Furthermore, patients with EBV-LELCC had higher sensitivity to anti-PD-1 treatment.

HEPATOLOGY INTERNATIONAL (2022)

Add to Collection

Review Oncology

Precision Medicine in Biliary Tract Cancer

Aaron J. Scott et al.

Summary: Precision medicine plays a crucial role in the treatment of biliary tract cancers. Targeted therapies have changed the therapeutic landscape for advanced BTC, and up to 40% of patients have potentially targetable molecular abnormalities. Combinational treatment strategies like immune checkpoint inhibition plus chemotherapy hold promise for improving outcomes in patients who cannot be targeted.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Immunotherapies in clinical development for biliary tract cancer

Arndt Vogel et al.

Summary: Currently, immune oncology has shown some positive signals in unselected BTC populations, but should not be considered as a preferred systemic treatment. In the coming years, understanding the molecular mechanisms underlying resistance to checkpoint inhibition and identifying positive predictive biomarkers will be crucial for successful integration of IO into treatment concepts for BTC patients.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses

Jihoon G. Yoon et al.

Summary: This study identified predictive molecular features of chemotherapy and immunotherapy responses in advanced BTCs using clinical sequencing platforms. The results offer an intuitive framework to guide treatment based on the tumors' molecular features.

HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma

Yu-Hua Huang et al.

Summary: The study investigated the clinicopathology, tumor immune microenvironment, and genomic landscape of Epstein-Barr virus (EBV)-associated intrahepatic cholangiocarcinoma (EBVaICC) in southern China, revealing unique characteristics and suggesting that patients with EBVaICC may benefit from immune checkpoint therapy.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Current and emerging therapies for advanced biliary tract cancers

Audrey E Kam et al.

Lancet Gastroenterology & Hepatology (2021)

Add to Collection

Article Oncology

Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients

Miao-Zhen Qiu et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Sarina A. Piha-Paul et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

Add to Collection

Review Oncology

Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma

Rong Tan et al.

CANCER COMMUNICATIONS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim et al.

NATURE MEDICINE (2018)

Add to Collection

Article Oncology

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients

Akihito Kawazoe et al.

GASTRIC CANCER (2017)

Add to Collection

Article Multidisciplinary Sciences

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le et al.

SCIENCE (2017)

Add to Collection

Review Virology

Integrins as Herpesvirus Receptors and Mediators of the Host Signalosome

Gabriella Campadelli-Fiume et al.

ANNUAL REVIEW OF VIROLOGY, VOL 3 (2016)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Oncology

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

Benjamin J. Chen et al.

CLINICAL CANCER RESEARCH (2013)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.